The National Cancer Institute (NCI) awarded a $849,371 Project Grant (CFDA 93.395 - Cancer Treatment Research) to The Washington University in St. Louis to develop methods for hijacking post-translational arginylation for targeted protein degradation in cancer research. The project aims to apply computational techniques to identify potential ATE1 binder hits, synthesize and evaluate these molecules, and establish arginylation-based protein degradation technology. The grant includes two sub-awards to the University of Florida and the University of Texas Health Science Center at San Antonio to collaborate on the computational drug discovery, synthesis, and mechanism of action studies related to this protein degradation approach. The award period runs from August 2, 2024 to July 31, 2026.
Generated 2/25/25, 2:55 AM